Harpoon Therapeutics, Inc.
Harpoon Therapeutics, Inc. (HARP): 3 pipeline candidates · ~6 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
5.8 months
D/E 9.48 · 0% dilution
Lead: Phase 1/Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for Harpoon Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$17.9M
Quarterly Burn
$16.5M
Runway
5.8 mo
Revenue
$4.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in Harpoon Therapeutics, Inc.'s pipeline?
Harpoon Therapeutics, Inc. (HARP) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Harpoon Therapeutics, Inc.'s lead drug candidate?
Harpoon Therapeutics, Inc.'s most advanced tracked candidate is hpn217 (Phase 1) for multiple myeloma.
What is Harpoon Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Harpoon Therapeutics, Inc. has approximately 5.8 months of cash runway.
Get the full picture on Harpoon Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.